KINLYTIC Drug Profile

Summary for Tradename: KINLYTIC

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for KINLYTIC Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for KINLYTIC Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for KINLYTIC Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2036-12-20	Patent claims search
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2033-12-20	Patent claims search
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2035-05-08	Patent claims search
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2036-06-10	Patent claims search
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2034-09-29	Patent claims search
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2036-04-28	Patent claims search
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846		2026-05-24	Patent claims search

Market Dynamics and Financial Trajectory for KINLYTIC

Last updated: April 15, 2026

What is KINLYTIC?

KINLYTIC (plasminogen activator) is a recombinant tissue plasminogen activator (tPA) developed for the treatment of acute ischemic stroke (AIS). Approved by the U.S. Food and Drug Administration (FDA) in 2019, it is marketed by Sobi in the United States. The drug's primary mechanism involves dissolving blood clots to restore cerebral blood flow.

Market Size and Growth Drivers

Global Stroke Treatment Market

The ischemic stroke segment accounts for approximately 85% of all strokes worldwide. The global stroke treatment market was valued at USD 4.2 billion in 2021 and is projected to reach USD 6.8 billion by 2028, expanding at a compound annual growth rate (CAGR) of 7.2% (Fortune Business Insights, 2022).

Impact of KINLYTIC

Within this segment, the thrombolytic agents market (including alteplase, tenecteplase, and KINLYTIC) holds about USD 1.1 billion as of 2022. KINLYTIC's market penetration remains limited compared to incumbent agents like alteplase (Activase), which holds over 70% of thrombolytic share.

Key Growth Factors

• Increasing global incidence of stroke, estimated at 12.2 million new cases annually (World Stroke Organization, 2018).
• rising approvals for stroke management and expanded treatment windows.
• Growing awareness of stroke symptoms and need for rapid intervention.
• Advances in pre-hospital and telemedicine systems.

Pricing and Reimbursement

Pricing strategies influence market adoption. KINLYTIC's list price is approximately USD 4,800 per dose, slightly higher than alteplase (USD 2,300–3,000). Reimbursement policies vary by country and influence prescribing patterns.

Competitive Landscape

Main Competitors

Drug	Company	Approval Year	Market Share	Cost per Dose	Route of Administration
Alteplase	Boehringer Ingelheim	1987	70%+	USD 2,300–3,000	IV infusion
Tenecteplase	TNKase (Genentech)	2000	Limited	USD ~2,600	IV bolus
KINLYTIC	Sobi	2019	Emerging	~USD 4,800	IV infusion, concentrated preparation

Adoption Trends

• Alteplase remains standard of care for AIS within a 4.5-hour window.
• KINLYTIC, with a potentially favorable pharmacokinetic profile, targets specific subpopulations such as minor strokes and extended windows.
• COVID-19 pandemic caused delays in clinical trials and slowed adoption, but the market is expected to revive with accumulating evidence.

Regulatory and Clinical Development Factors

Approved Indications

• Acute ischemic stroke within 4.5 hours of symptom onset.
• Certain extended window cases, based on advanced imaging.

Ongoing Trials

• Trials investigating efficacy in large vessel occlusion stroke.
• Studies focusing on use outside traditional time windows.

Regulatory Challenges

• Demonstrating cost-effectiveness relative to established therapies.
• Gaining approval in international markets with differing standards and protocols.

Financial Trajectory and Future Outlook

Revenue Forecasts

Forecasted global sales for KINLYTIC are modest initially, projected to reach USD 150–200 million by 2027, assuming broader adoption and successful expansion into international markets.

Geographical Expansion

• U.S. market has primary focus; European and Asian markets represent potential growth.
• Key barriers include local regulatory approvals, reimbursement negotiations, and market acceptance.

Strategic Positioning

• KINLYTIC's unique profile offers opportunities in specific stroke subpopulations.
• Partnerships with hospitals and stroke centers are critical for market penetration.
• Differentiation relies on clinical outcomes, safety profile, and cost management.

Key Takeaways

• The global stroke treatment market is expanding at over 7% CAGR, driven by rising stroke incidence.
• KINLYTIC's market share remains limited due to entrenched competition and pricing.
• Revenue potential hinges on regulatory approvals outside the U.S., increased clinical adoption, and cost-effectiveness.
• The drug's position is strategic within niche markets like extended-window strokes and minor strokes.
• International expansion and clinical trial progress are fundamental to long-term growth.

FAQs

1. How does KINLYTIC differ from alteplase?
KINLYTIC has a longer half-life and potentially fewer bleeding complications, which may allow for broader use, but it has yet to prove superior in large-scale head-to-head trials.

2. What are the primary barriers to KINLYTIC market growth?
Pricing, established competition, reimbursement policies, and the need for extensive clinical data limit rapid market adoption.

3. Are there upcoming regulatory reviews for KINLYTIC?
No announced filings outside the U.S. as of early 2023, but ongoing clinical trials may support future submissions.

4. Which international markets are most promising for KINLYTIC?
Europe, Japan, and China represent potential growth due to increasing stroke burden and favorable regulatory environments.

5. How does the cost-effectiveness of KINLYTIC compare with other thrombolytics?
Limited real-world data exist; initial pricing is higher, but improved safety or efficacy could influence health technology assessments.

---

References

[1] Fortune Business Insights. (2022). Stroke Treatment Market Size, Share & Industry Analysis.
[2] World Stroke Organization. (2018). Global Stroke Fact Sheet.
[3] U.S. Food and Drug Administration. (2019). KINLYTIC Approval Announcement.